Our product is the COBRA™ (Control Of Bleeding, Resuscitation, with Artery occlusion), which stops bleeding as early as possible to allow for safe patient transport to definitive care. Our primary revenue source will be B2B sales - specifically hospitals, trauma/surgical centers, ambulatory care, and armed forces.